Neurology Specific Literature Search   
 
[home][thesaurus]
    
Click Here to return To Results

 

Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
See this aricle in Pubmed

Article Abstract
Lecanemab reduced markers of amyloid in early Alzheimers disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was associated with adverse events. Longer trials are warranted to determine the efficacy and safety of lecanemab in early Alzheimers disease.
 
Related Tags
(click to filter results - removes previous filter)

adverse drug reaction
Alzheimer's disease
Alzheimer's disease,early onset
Alzheimer's disease,treatment of
amyloid beta protein
amyloid-related imaging abnormalities
biologic markers
confusion
dementia
dementia,treatment of
dizziness
headache
hemosiderosis of CNS,superficial
intracerebral hemorrhage
lecanemab
microhemorrhage,intracerebral
monoclonal antibodies
safety
tissue plasminogen activator,intravenous
treatment of neurologic disorder

Click Here to return To Results